Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Corvus Pharmaceuticals, Inc. - Common Stock
(NQ:
CRVS
)
20.98
+0.28 (+1.35%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Corvus Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting
March 14, 2023
Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad...
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharma's HIV Candidate Shows Potential To Prevent Virus Re-Emergence
↗
February 21, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
February 21, 2023
Via
Benzinga
Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal
February 21, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 10, 2022
↗
March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...
Via
Benzinga
$1 Million Bet On BioCardia? Check Out These 4 Penny Stocks Insiders Are Buying
↗
December 21, 2022
The Dow Jones settled higher on Tuesday after recording losses for four straight sessions. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
4 Penny Stocks Insiders Are Buying: Getaround, Corvus Pharmaceuticals And More
↗
December 16, 2022
The Dow Jones closed lower by over 700 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...
Via
Benzinga
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
↗
December 13, 2022
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
Via
Benzinga
Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
December 12, 2022
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022
December 05, 2022
Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PT
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology
November 14, 2022
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
November 03, 2022
Company to host conference call and webcast on December 12, 2022 at 4:30 pm ET / 1:30 pm PT
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Preview For Corvus Pharmaceuticals
↗
November 02, 2022
Corvus Pharmaceuticals (NASDAQ:CRVS) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022
October 27, 2022
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer
October 25, 2022
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2022
↗
October 07, 2022
Upgrades
Via
Benzinga
10 Best Stocks to Buy Now According to Jeffrey Diehl’s Adams Street Partners
↗
October 05, 2022
In this article, we will be taking a look at some of the top stocks in the portfolio of Jeffrey Diehl.
Via
Talk Markets
Corvus Pharma's Partner Secures China Approval For Early-Stage Mupadolimab Trial For Lung, Head & Neck Cancer
↗
September 27, 2022
Via
Benzinga
Corvus Pharmaceuticals: Q2 Earnings Insights
↗
August 08, 2022
Corvus Pharmaceuticals (NASDAQ:CRVS) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Recap: Corvus Pharmaceuticals Q4 Earnings
↗
March 10, 2022
Corvus Pharmaceuticals (NASDAQ:CRVS) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
A Preview Of Corvus Pharmaceuticals's Earnings
↗
March 09, 2022
Corvus Pharmaceuticals (NASDAQ:CRVS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement....
Via
Benzinga
The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake
↗
January 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Corvus Says Chinese Angel Pharma Starts Phase 1/2 Blood Cancer Study Corvus...
Via
Benzinga
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
↗
June 28, 2022
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.
Via
Benzinga
Carnival Surges Over 12%, Here's 75 Biggest Movers From Friday
↗
June 27, 2022
Gainers USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Schenker and USA Truck announced plans to combine and create premier North American transportation...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
December 17, 2021
Gainers GBS (NASDAQ:GBS
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
April 20, 2022
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...
Via
Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
↗
March 06, 2022
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
December 01, 2021
Gainers Ardelyx (NASDAQ:ARDX) stock increased by 19.29% to $1.36 during Wednesday's pre-market session. The market value of their outstanding shares is at $153.3...
Via
Benzinga
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
↗
November 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
